Intelligent Bio Solutions Eyes Expansion with New Patent
Intelligent Bio Solutions Inc. (Nasdaq: INBS), a pioneering medical technology company dedicated to delivering smart, rapid, and non-invasive testing solutions, is on the verge of a significant milestone with the anticipated grant of its sixth patent in the United States. This upcoming patent is expected to bolster the protection of its innovative lateral flow technology, which is integral to the Intelligent Fingerprinting Drug Testing Solution, thereby reinforcing the company’s competitive edge.
Strengthening Intellectual Property Portfolio
The expected patent grant will enhance Intelligent Bio Solutions' already robust intellectual property portfolio. This protects its unique fingerprint sweat-based drug screening method, ensuring that the company is well-equipped to safeguard its technologies as it gears up for further penetration in the U.S. market.
A Voice from Leadership
Harry Simeonidis, the President and CEO of Intelligent Bio Solutions, emphasized the importance of this patent in their strategy, stating, “Protecting our proprietary technology is critical as we plan to scale our footprint in the U.S. drug screening market. This expected patent will further strengthen our portfolio and secure the innovation behind our drug testing solution.” His insights illuminate the strategic direction of the company and their commitment to innovation.
Rising Demand for Safe Drug Testing Solutions
As industries across the spectrum prioritize workplace safety and compliance, the demand for efficient and non-invasive drug testing solutions continues to rise. Intelligent Bio Solutions is uniquely positioned to meet this growing need with its proprietary technology that offers an alternative to traditional drug screening methods. The company’s innovative sweat-based approach, coupled with a recent FDA 510(k) submission, places it on the cusp of expansion in the U.S. market, projected for later this year.
The Future is Bright for Intelligent Bio Solutions
Looking ahead, more details regarding the patent grant will be disclosed once it officially issues. This milestone is not merely a legal victory; it is a testament to Intelligent Bio Solutions' commitment to pioneering advancements in drug testing technologies.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is at the forefront of medical technology, delivering innovative, rapid, non-invasive testing solutions. The company believes its Intelligent Fingerprinting Drug Screening System has the potential to transform portable testing through advanced fingerprint sweat analysis. This robust system aims to provide hygienic, cost-effective drug screening for common workplace substances, including opiates, cocaine, methamphetamine, and cannabis. Capable of collecting samples in seconds and producing results in under ten minutes, this innovative technology is projected to become an essential tool for employers in safety-critical sectors such as construction, manufacturing, engineering, transport, logistics, drug treatment, and coroner services.
Frequently Asked Questions
What is the significance of the anticipated patent for Intelligent Bio Solutions?
The anticipated patent will enhance the protection of its lateral flow technology, strengthening its position in the competitive drug testing market.
How does Intelligent Bio Solutions conduct its drug testing?
Intelligent Bio Solutions uses a non-invasive fingerprint sweat-based method that screens for a range of commonly abused substances.
What market sectors does Intelligent Bio Solutions cater to?
They provide solutions to various sectors, including construction, manufacturing, transport, logistics, and drug treatment organizations.
What future plans does Intelligent Bio Solutions have for the U.S. market?
Intelligent Bio Solutions has strategic plans to enter the U.S. market in 2025, backed by its innovative technologies and anticipated patent grants.
Who can be contacted for more information about Intelligent Bio Solutions?
The company can be reached at info@ibs.inc for general inquiries, while investor relations can be contacted through Valter Pinto at KCSA Strategic Communications through INBS@kcsa.com.
